PMID- 31727344
OWN - NLM
STAT- MEDLINE
DCOM- 20200117
LR  - 20200117
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 46
IP  - 4-5
DP  - 2019 Aug-Oct
TI  - A systematic review on the emerging association between the occurrence of 
      immune-related adverse events and clinical outcomes with checkpoint inhibitors in 
      advanced cancer patients.
PG  - 362-371
LID - S0093-7754(19)30128-9 [pii]
LID - 10.1053/j.seminoncol.2019.10.003 [doi]
AB  - The correlation between clinical outcomes and treatment-related adverse events 
      (AEs) has always been a debated topic in clinical oncology. Despite toxicities 
      pharmacodynamics effects, the misunderstanding has always been around the corner: 
      AEs themselves could lead to morbidity and mortality; on the other hand, the 
      choice of the clinical outcomes to measure is not univocal. After the advent of 
      immune checkpoint inhibitors (ICIs), such as anti-cytotoxic 
      T-lymphocyte-associated protein 4 and anti-programmed death-1/programmed death 
      ligand-1, new class-specific AEs have emerged, called immune-related AEs (irAEs). 
      With irAEs, the correlation between toxicity and clinical outcomes has suddenly 
      been suggested, but it is still to be proven. We conducted a systematic 
      literature review regarding this emerging association, pointing out all the 
      available data and speculating on the possible underlying mechanisms. Thirty-six 
      studies were included in the analysis, involving different malignancies (mostly 
      melanoma and lung cancer), with different measured clinical outcomes. The most of 
      them were retrospective. Despite the high heterogeneity, and the enormous biases 
      of the revised studies, we can assume that irAEs occurrence is linked to the 
      therapeutic activity of immune checkpoint inhibitors, with a (certain) direct 
      proportionality, maybe subtending the likelihood of an immunogenic phenotype. 
      This phenomenon seems to occur with both anti-cytotoxic T-lymphocyte-associated 
      protein 4 and anti-programmed death-1/programmed death ligand-1, and across 
      different solid malignancies.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Cortellini, Alessio
AU  - Cortellini A
AD  - Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy; Department of 
      Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, 
      Italy. Electronic address: alessiocortellini@gmail.com.
FAU - Buti, Sebastiano
AU  - Buti S
AD  - Medical Oncology, University Hospital of Parma, Parma, Italy.
FAU - Agostinelli, Veronica
AU  - Agostinelli V
AD  - Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy; Department of 
      Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, 
      Italy.
FAU - Bersanelli, Melissa
AU  - Bersanelli M
AD  - Medical Oncology, University Hospital of Parma, Parma, Italy; Medicine and 
      Surgery Department, University of Parma, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20191107
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use
MH  - Biomarkers, Tumor/antagonists & inhibitors
MH  - Drug-Related Side Effects and Adverse Reactions/diagnosis/*epidemiology/*etiology
MH  - Humans
MH  - Molecular Targeted Therapy/adverse effects
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplasms/*complications/diagnosis/drug therapy/*epidemiology
MH  - Patient Outcome Assessment
MH  - Public Health Surveillance
OTO - NOTNLM
OT  - Anti-CTLA-4
OT  - Anti-PD-1
OT  - Anti-PD-L1
OT  - Cancer
OT  - Clinical outcomes
OT  - Immune-related adverse events
OT  - Immunotherapy
EDAT- 2019/11/16 06:00
MHDA- 2020/01/18 06:00
CRDT- 2019/11/16 06:00
PHST- 2019/06/20 00:00 [received]
PHST- 2019/10/16 00:00 [revised]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2020/01/18 06:00 [medline]
PHST- 2019/11/16 06:00 [entrez]
AID - S0093-7754(19)30128-9 [pii]
AID - 10.1053/j.seminoncol.2019.10.003 [doi]
PST - ppublish
SO  - Semin Oncol. 2019 Aug-Oct;46(4-5):362-371. doi: 10.1053/j.seminoncol.2019.10.003. 
      Epub 2019 Nov 7.